• Male or female participants must be 40 to 80 years of age inclusive, at the time of signing

• the ICF.

• Demonstrate acceptable MDI administration technique at Visit 1 (V1) and Visit 2 (V2)

• A diagnosis of COPD confirmed by a post-bronchodilator FEV1/FVC ratio \< 70%

• at V1.

• Current or former smokers with a history of at least 10 pack-years of cigarette smoking;

• defined as (number of cigarettes per day/20) x number of years smoked. Previous smokers are defined as those who have stopped smoking for at least 6

• months prior to V1.

• A baseline peripheral blood eosinophil count of ≥ 100 cells/mm3 assessed at Visit 1 by

• the central laboratory

• A CAT score of ≥ 10 at Visit 1.

• Participant must fulfill at least 1 of the 4 CV disease/risk factor criteria below \[(a), (b),

• (c), or (d)\]:

‣ : Established CV Disease

‣ : Combination of CV risk factors:

⁃ Hypertension

• Diabetes Mellitus

• Chronic Kidney Disease

• Dyslipidemia

• Obesity

‣ : High risk of CV disease determined using an established CV risk assessment

∙ tool.

‣ : CT coronary Artery Calcification

• Willing and, in the opinion of the investigator, able to adjust current COPD therapy, as

• required by the protocol.

• Willing to visit at the study site or participate in virtual visits as required per the protocol

• to complete all study assessments.

⁃ A female is eligible to enter and participate in the study if the female is of:

∙ Non-childbearing potential: either permanently sterilized or who are post-menopausal.

‣ Childbearing potential: has a negative serum pregnancy test at V1 and must use one

⁃ highly effective form of birth control.

⁃ Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.